Galectin-1 (gal-1), an endogenous b-galactoside-binding protein, triggers T-cell death through several mechanisms including the death receptor and the mitochondrial apoptotic pathway. In this study we first show that gal-1 initiates the activation of c-Jun N-terminal kinase (JNK), mitogen-activated protein kinase kinase 4 (MKK4), and MKK7 as upstream JNK activators in Jurkat T cells. Inhibition of JNK activation with sphingomyelinase inhibitors (20 lM desipramine, 20 lM imipramine), with the protein kinase C-d (PKCd) inhibitor rottlerin (10 lM), and with the specific PKCh pseudosubstrate inhibitor (30 lM) indicates that ceramide and phosphorylation by PKCd and PKCh mediate gal-1-induced JNK activation. Downstream of JNK, we observed increased phosphorylation of c-Jun, enhanced activating protein-1 (AP-1) luciferase reporter, and AP-1/DNA-binding in response to gal-1. The pivotal role of the JNK/c-Jun/AP-1 pathway for gal-1-induced apoptosis was documented by reduction of DNA fragmentation after inhibition JNK by SP600125 (20 lM) or inhibition of AP-1 activation by curcumin (2 lM). Gal-1 failed to induce AP-1 activation and DNA fragmentation in CD3-deficient Jurkat 31-13 cells. In Jurkat E6.1 cells gal-1 induced a proapoptotic signal pattern as indicated by decreased antiapoptotic Bcl-2 expression, induction of proapoptotic Bad, and increased Bcl-2 phosphorylation. The results provide evidence that the JNK/c-Jun/AP-1 pathway plays a key role for T-cell death regulation in response to gal-1 stimulation.
Apoptosis in the immune system is a process that ensures the proper removal of autoreactive T cells during thymic development and T-cell homeostasis as well as the downregulation of peripheral immune responses against antigens. Thus T-cell apoptosis is essential for induction of central and peripheral tolerance and for prevention of autoimmunity. 1 Peripheral autoreactive lymphocytes can be deleted by developmental arrest (anergy) or by apoptosis through receptor-mediated activation-induced cell death (AICD). Following an immune response most of the activated T cells need to be deleted by apoptosis, which requires a switch from an apoptosisresistant to an apoptosis-sensitive state. This can be mediated by cytokines, death receptors, and proapoptotic proteins. 2 Apoptosis can be initiated by two different pathways: the receptor-mediated AICD and the intrinsic mitochondria-dependent pathway. 3, 4 Both pathways ultimately activate a cascade of cysteine proteases (caspases) and cells are committed to death thereby terminating immune responses. Galectin-1 (gal-1), a prototype member of the family of endogenous b-galactoside-binding proteins, is widely expressed in lymphoid and nonlymphoid tissues and confers a variety of immunoregulatory functions. Functional gal-1 is a homodimer of noncovalently associated 14 kDa subunits with two carbohydrate recognition domains. This enables cell adhesion and cross-linking of several glycoproteins preferentially with branched or repeating Galb1-4GlcNAc sequences on T cells including the signaling proteins CD2, CD3, CD7, CD43, and CD45. [5] [6] [7] [8] [9] Gal-1 induces apoptosis of immature cortical thymocytes, activated T cells, and T-cell lines, 7, 9, 10 but also sensitizes resting human T lymphocytes to Fas Apo-1, CD95)-mediated cell death. 11 Gal-1 is exported by an endoplasmic reticulum/Golgi-independent pathway and is presented by cell-surface glycoconjugates. 12 It has been shown that gal-1 presented by extracellular matrix more effectively induces apoptosis of susceptible T cells than the soluble form. 13 Gal-1 synthesis is strongly upregulated after peptide antigen-induced activation of murine T cells and inhibits antigen-induced proliferation of activated T cells. 14 These data strongly suggest a potential autocrine suicide mechanism to achieve homeostasis during termination of an immune response. CD4 þ CD25 þ regulatory T (T reg ) cells express gal-1 at high level and this expression is upregulated upon T-cell receptor (TCR) activation. 15 Surface-bound gal-1 was found to be a key effector of regulation mediated by T reg cells, which is consistent with the non-antigen-specific nature of suppression. The secretion of gal-1 by decidual natural killer cells, its abundance in various cell types of human placenta, and the involvement in apoptotic depletion of alloreactive T cells contribute to the generation of an immune-privileged environment at the maternal-fetal interphase. 16 Although cancer patients develop adaptive immune responses, tumors evade an effective immunosurveillance by induction of T-cell apoptosis. 17 Increased gal-1 expression by activated tumor endothelial cells may locally contribute to the apoptotic elimination of infiltrating effector T cells and favor tumor progression. 18 Blockage of gal-1 expression stimulates the generation of a tumor-specific T-cell-mediated response and tumor rejection in a syngeneic model of murine melanoma. 19 It has been suggested that the gal-1 death pathway in T cells is entirely different from that mediated by Fas/FasL or glucocorticoids. 7 However, recent data have shown that gal-1 cooperates with Fas-induced apoptosis in peripheral T cells 11 and stimulates the death receptor pathway in human Jurkat T lymphocytes. 20 Caspase activation has been shown by several authors as death effectors, 21, 22 although it has been reported that gal-1 induces T-cell death in a caspaseand cytochrome c-independent manner by translocation of endonuclease G from mitochondria to the nucleus. 23 Activation of the activating protein-1 (AP-1) transcription factor and downregulation of Bcl-2 have also been shown after exposure to gal-1. 24 Gal-1-induced activation of the TCRz/Lck/ZAP70 pathway was proved to be essential to stimulate ceramide release and to trigger the mitochondrial pathway of apoptosis. 25 The stimulation of the mitochondrial apoptotic pathway by gal-1 initiated ceramide release 21 and the requirement of AP-1 for ceramide-induced apoptosis 26 prompted us to investigate the role of the JNK/c-Jun/AP-1 pathway for cell death.
In this study we could show that gal-1 induces the activation of c-Jun N-terminal kinase (JNK), the phosphorylation of c-Jun, enhanced AP-1 luciferase reporter, and AP-1/DNAbinding activities as measured by immunoblot analyses, kinase assays, reporter and gel shift assays, and by enzyme-linked immunosorbent assay (ELISA). The results provide evidence for a pivotal role of the JNK/c-Jun/AP-1 pathway for T-cell death regulation.
Results
Evidence for a role of the JNK/c-Jun/AP-1 pathway in gal-1-induced cell death. Jurkat T lymphocytes exposed to gal-1 for 6 h underwent apoptosis as indicated by DNA fragmentation (Figure 1 ). To elucidate the role of JNK and AP-1 for gal-1 induced death, we preincubated the cells with the reversible ATP-competitive JNK inhibitor SP600125 (10 mM, 20 mM) and with curcumin (2 mM), an inhibitor of AP-1 activation. Both inhibitors effectively blocked gal-1-stimulated DNA fragmentation in Jurkat E6.1 cells (Figure 1 ). DNA fragmentations and inhibition by SP600125 were also recorded in gal-1-treated CCRF-CEM cells indicating that this effect was not specific for Jurkat T cells (Figure 1) . Interestingly, gal-1 failed to generate DNA fragmentation in CD3-deficient Jurkat J31-13T cells, which shows defects in gal-1-induced TCR/CD3 signaling. 8 Gal-1 induces JNK activation. Next we studied whether gal-1 is able to activate JNK and its downstream pathways to T-cell death. The inhibition of gal-1-induced DNA fragmentation with the specific JNK inhibitor SP600125 indicated that JNK is involved in the apoptotic pathway. Western blot analysis revealed that the stimulation of Jurkat T cells with gal-1 effectively increased the dual phosphorylation of JNK1 and JNK2 (Figure 2a) . JNK phosphorylation in Jurkat T cells by gal-1 (50 mg/ml) could be blocked by the disaccharidic competitor lactose (30 mM), the protein kinase C-d (PKCd) inhibitor rottlerin (10 mM), and the specific PKCy pseudosubstrate inhibitor (30 mM). JNK activation was additionally verified by kinase assays as indicated by increased phosphorylation of JNK substrates in a time-dependent manner (Figures 2b and  c) . Exposure of the cells with the specific JNK inhibitor SP600125 (10 mM) or stimulation of the cells with gal-1 (50 mg/ml) in the presence of asialofetuin (50 mM) decreased the phosphorylation of the JNK substrate to the level of control cells (Figure 2b) . Furthermore, treatment of the cells with the sphingomyelinase inhibitors imipramine and desipramine (20 mM) before stimulation with gal-1 strongly reduced the activation of JNK, whereas myricetin (10 mM), an ATPcompetitive inhibitor of mitogen-activated protein kinase kinase 4 (MKK4), showed only marginal inhibitory effects (Figure 2c ). The data suggest that PKCd, PKCy, and MKK4 Gal-1 activated MKKs in Jurkat E6.1 cells. The stimulating effects of gal-1 on JNK phosphorylation and inhibition of JNK substrate phosphorylation by myricetin prompted us to investigate whether cell stimulation also induces the phosphorylation and activation of MKK4, MKK7, and MKK3/6. MKK7 is a specific upstream JNK activator, MKK4 phosphorylates JNK and p38 MAP kinase groups whereas MKK3/6 are specific for p38 MAP kinase. 28 Effects of gal-1 on pro-and antiapoptotic proteins. Different AP-1 dimer combinations may recognize different sequence elements in the promoter and enhancer regions of target genes. 30 Therefore, it is conceivable that AP-1 differentially regulates pro-and antiapoptotic genes in response to extracellular stimuli. Gal-1 moderately decreased Bcl-2 protein expression in agreement with previous studies 21, 24 ( Figure 7 ). However, we recorded a significant upregulation of proapoptotic Bad expression by gal-1 before the onset of DNA fragmentation. Inhibition of JNK with SP600125 and of AP-1 activation with curcumin 26 blocked the upregulation of Bad (Figure 7 ). Western blot analysis and densitometric quantification of the immunoreactive protein bands revealed that gal-1 triggered the dual phosphorylation of Bcl-2 on serine 70 and threonine 56 ( Figure 7 ) that suppresses its antiapoptotic function. 31, 32 Inhibition of JNK with SP600125 blocked the phosphorylation at both sites indicating that JNK functions as a Bcl-2 kinase (Figure 7 ).
Gal-1-induced processing of procaspase-9 and procaspase-3 required the JNK/c-Jun/AP-1 pathway. Downregulation and phosphorylation of Bcl-2 as well as upregulation of Bad may induce depolarization of mitochondria and subsequent translocation of cytochrome c into the cytosol. Because cytochrome c is essentially required for procaspase-9 activation, we investigated the effects of gal-1 on initiator procaspase-9 and downstream effector procaspase-3 fragmentation. Processing of procaspase-9 and procaspase-3 was detectable 4 h after stimulation of Jurkat E6.1 cells with gal-1 and cleavage products further increased with exposure time (Figure 8) . Blocking of the JNK/c-Jun/AP-1 pathway by SP600125 impeded the subsequent activation of both procaspases (Figure 8 ).
Discussion
There is cumulative evidence that JNK has an essential role in apoptosis induced by UV radiation, growth factor withdrawal, chemotherapeutic drugs, and ceramide. 33, 34 In this study we could show that JNK activation is also required for apoptosis of human lymphoblastoid Jurkat T cells induced by gal-1. JNK activation occurred rapidly within 10 min after gal-1 exposure, as shown by kinase assays and increasing levels of phospho-JNK1 and phospho-JNK2 isoforms. Apoptotic cell death is significantly promoted in cells expressing JNK, but effectively suppressed in cells expressing a dominant-negative JNK1 mutant or JBD, a JNK inhibitor protein. 34 In agreement with these data we also found that JNK activation is efficiently prevented by the reversible ATP-competitive inhibitor of JNK SP600125 and this perturbation of JNK activation resulted in prevention of DNA fragmentation.
In a recent report we verified that gal-1-induced DNA laddering corresponds to phosphatidylserine exposure and DNA-strand breaks as analyzed by TUNEL assay. 20 However, in some T-cell lines gal-1-induced phosphatidylserine translocation was not associated with apoptotic progression. 35 Therefore, we studied the inhibitory effects of SP600125 and curcumin on gal-1-induced apoptosis in Jurkat E6.1 and CCRF-CEM cells by DNA fragmentation as a reliable apoptotic marker.
JNK activity is differentially regulated by various different upstream kinases including MKK4, MKK7, PKCd, ASK1, and mixed lineage kinases. 27, 28, 34, 36 Thus, the blockade of JNK activation by inhibitors of PKCy, PKCd, and MKK4 is consistent with these data. Interestingly, JNK, MKK4, and MKK7 activities increased in parallel after gal-1 stimulation indicating that these kinases are linked. Lactose and asialofetuin completely inhibited JNK activation providing evidence that gal-1 prefers glycoproteins with biantennary and triantennary N-linked glycan chains presenting terminal Galb1-4GlcNAc sequences for recognition available on asialofetuin. 36 Therefore, the differential glycosylation state of cell-surface glycoproteins during immune cell activation and differentiation can selectively regulate cellular signaling. This may explain the unequal susceptibility of effector T-cell subsets to gal-1-induced cell death. 37 There is experimental evidence that gal-1 induces partial TCRz-chain phosphorylation generating inhibitory pp21z, limits receptor clustering at the TCR contact site, 38 and promotes apoptosis. Deficiency in p56 lck and ZAP70 tyrosine kinases abolishes gal-1-induced T-cell death, and reexpres- sion restores apoptosis. 25 The results of our study support these data, as gal-1 failed to induce DNA fragmentation of CD3-deficient J31-13 cells. Gal-1 also initiates the sphingomyelinase-mediated release of ceramide of activated peripheral and leukemic T cells. Further downstream events such as the decrease of antiapoptotic Bcl-2, depolarization of mitochondria, and activation of caspase-9 and caspase-3 depend on increased ceramide levels. Ceramide production and all the downstream events require the presence of the protein tyrosine kinases p56 lck and ZAP70. 21 We show here that blocking of ceramide production by desipramine and imipramine abrogated the induction of JNK activity by gal-1. To exert its proapoptotic effects, it seems that ceramide transduces the intracellular signals by activating JNK. 33 Furthermore, our study result shows that Bcl-2 undergoes increased phosphorylation by JNK in Jurkat E6.1 cells as JNK inhibition by SP600125 effectively decreased the phosphorylation of Bcl-2. The inhibition of Bcl-2 phosphorylation by SP600125 below the basal level in absence of gal-1 emphasizes the role of JNK as Bcl-2 kinase (Figure 7) . The phosphorylation of Bcl-2 decreases its ability to heterodimerize with proapoptotic Bax. 31, 32 Thus, JNK-mediated phosphorylation of Bcl-2 suppresses its antiapoptotic function in mitochondria-related cell death mechanisms.
Our study results further show a gal-1-induced signaling pathway that connects the activation of JNK, the selective phosphorylation of c-Jun, and the activation of the AP-1 transcription factor complex. 30, 39 Blocking of JNK activation by SP600125 or inhibition of ceramide generation with imipramine and desipramine effectively decreased gal-1-induced phosphorylation of c-Jun and the AP-1 luciferase reporter activity of Jurkat E6.1 cells. Gal-1 induced the AP-1 reporter construct to a lesser extent in CCRF-CEM cells, however, failed to activate the construct in CD3-deficient J31-13 cells. This indicates that TCR/CD3 signaling is required for initiation of apoptosis. 40 Gel shift assays and analysis of immobilized AP-1/oligonucleotide complexes by ELISA revealed that gal-1 rapidly enhanced the binding of the AP-1 complex to the TRE and induced differential increases of the AP-1 proteins phospho-c-Jun, phospho-JunD, c-Fos, Jun B, and Fos B. This suggests that gal-1 promotes the assembly of various dimer combinations with cell-and stimulus-specific transcriptional activities. 30, 41 Inhibition of c-Jun/AP-1 binding to its TRE site by curcumin may be responsible for the subsequent inhibitory effects on c-Jun/AP-1-mediated gene expression. 42 Gal-1-stimulated phosphorylation of c-Jun and the increased levels of phosphorylated c-Jun and JunD of AP-1 oligonucleotide complexes may also contribute to AP-1 activation. 30 Blocking of DNA fragmentation by exposure of Jurkat E6.1 cells to curcumin and to the JNK inhibitor SP600125 before gal-1 stimulation suggests a pivotal role of the JNK/c-Jun/AP-1 pathway for apoptosis. In gal-1-induced cells, the upregulation of Bad in conjunction with low levels of antiapoptotic Bcl-2 and its increased phosphorylation generate a proapoptotic cascade leading to cytochrome c-mediated initiator procaspase-9 and downstream effector procaspase-3 activation. 22 In line with our previous study that showed a gal-1-induced coincidence of cytochrome c release and caspase-9 activation, the present data can be interpreted as a clear sign for involvement of the mitochondrial compartment in gal-1-induced apoptosis. 22 The data presented in this study provide the first experimental evidence indicating the pivotal role of JNK as well as of c-Jun/AP-1, Bcl-2, and Bad as targets of the signal transduction pathway triggered in gal-1-induced apoptosis. A profound knowledge about the immunoregulatory mechanisms of gal-1 on T cells opens the perspective to use this endogenous lectin for immunomodulatory strategies in autoimmune diseases, infection, and cancer. Figure 7 Effects of galectin-1 (gal-1) on Bcl-2 and Bad protein levels and on Bcl-2 phosphorylation. Jurkat E6.1 cells were cultured with curcumin for 14 h and with SP600125 for 30 min. Non-and inhibitor-treated cells (2 Â 10 6 cells per well) were stimulated with gal-1 for the periods of time as indicated. Control cells were incubated in medium alone. Cell extract proteins were analyzed on the blots with a Bcl-2 polyclonal antibody (pAb), Bad pAb, phospho-Bcl-2 (Ser70) monoclonal antibody (mAb), and with a phospho-Bcl-2 (Thr56) pAb. The bands were luminographically visualized on X-ray films by enhanced chemiluminescence (ECL). Equal loading of gel lanes was verified by the expression of b-actin. Phospho-Bcl-2 bands were analyzed by densitometry using the Odyssey application software (version 3.0.16) from LICOR (Bad Homburg, Germany). Data are expressed as xfold relative to the control after normalization to the corresponding b-actin bands (loading). Shown are representative blots from three independent experiments ribonuclease A, SDS, SP600125 (anthra(1,9-cd)pyrazol-6(2H)-one), Tris, and Triton X-100 were from Sigma (Deisenhofen, Germany). Aprotinin, DNA molecular weight marker 100 bp ladder, leupeptin, pepstatin, pefabloc, poly[dI-dC], proteinase K, and T4 polynucleotide kinase were purchased from Roche Molecular Biochemicals (Mannheim, Germany) and JNK1 polyclonal antibody (pAb), c-Jun(1-169)-GST were from Biomol (Hamburg, Germany). Fetal calf serum (FCS), kanamycin, RPMI 1640 medium were from Gibco BRL (Eggenstein, Germany), enhanced chemiluminescence (ECL) detection reagents, Hybond ECL nitrocellulose membranes, protein G agarose, PVDF membranes, and [g-32 P]ATP were from GE Healthcare Europe (Freiburg, Germany). Rottlerin and the PKCy pseudosubstrate inhibitor (Myr-LHQRRGAIKQAKVHHVKC-NH 2 ) were from MerckBiosciences (Schwalbach, Germany). The reporter gene constructs, pAP1(PMA)-TA-Luc and pTA-Luc, were from Clontech (Heidelberg, Germany) and actin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) pAb, double-stranded AP-1 consensus (sc-2501), and the mutant (sc-2514) oligonucleotide were from Santa Cruz Biotechnology (Heidelberg, Germany). Bad pAb, Bcl-2 pAb, phospho-Bcl-2 (Ser70) monoclonal antibody (mAb), phospho-Bcl-2 (Thr56) pAb, cleaved caspase-9 (Asp315) pAb, cleaved caspase-3 (Asp175) rabbit mAb, phospho-c-Jun (Ser63) pAb, phospho-c-Jun (Ser63) blocking peptide, phospho-c-Jun (Ser73) pAb, phospho-c-Jun (Ser73) blocking peptide, phospho-MKK3/6 (Ser189/Thr207) mAb, phospho-MKK7 (Ser271/Thr275) pAb, phospho-JNK (Thr183/Tyr185) mAb, phospho-MKK4 (Ser257/Thr261) pAb, and the JNK assay kit were from New England Biolabs (Frankfurt, Germany). The Trans-AM AP-1 transcription factor assay kit was from Active Motif North America (Carlsbad, CA, USA).
Cell lines. The human leukemic T-cell line Jurkat (clone E6.1; European Collection of Cell Cultures, Salisbury, UK) and the CD3-deficient Jurkat 31-13 cell clone, kindly provided by A. Alcover (Institut Pasteur, Paris, France), were maintained at 371C and 5% CO 2 in RPMI 1640 medium supplemented with 10% FCS and 10 mg/ml kanamycin. Human CCRF-CEM lymphoblastic leukemia T cells (DSMZ -Search for Human and Animal Cell Lines, Braunschweig, Germany) were cultured in RPMI 1640 medium containing 10% FCS, penicillin (100 mU/ml), and streptomycin (50 mg/ml).
Preparation of recombinant human gal-1. The preparation of gal-1 cDNA, ligation into the isopropyl-b-D-thiogalactopyranoside-inducible expression vector pET22b( þ ), and expression in E. coli were performed as previously described. 20 After cell lysis in EDTA-MEPBS (20 mM Na 2 HPO 4 (pH 7.2), 150 mM NaCl, 4 mM 2-mercaptoethanol, 2 mM EDTA) by sonication on ice, gal-1 was purified by affinity chromatography on lactosyl agarose. 43 The gal-1 protein was verified as a 14 kDa band in silver-stained sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels.
AP-1 reporter gene assay. The pAP1(PMA)-TA-Luc cis-reporter vector and the pTA-Luc vector as a negative control are designed for monitoring the induction of AP-1-mediated signaling events by assaying the luciferase activity. The cells (1 Â 10 7 per 0.8 ml RPMI 1640 medium) mixed with 25 mg of the reporter constructs were electroporated in 0.4 cm cuvettes with a gene pulser from Bio-Rad (Munich, Germany) at 350 V and 900 mF. Then the cells were cultured at 5 Â 10 6 per 4 ml RPMI 1640 medium for 30 min at 371C without or with SP600125 followed by stimulation with gal-1 without or in the presence of lactose or asialofetuin for 3 h as indicated in the figure legend. Cell lysis and the measurement of reporter luciferase activity were performed by applying the luciferase assay system (Promega, Mannheim, Germany).
Preparation of nuclear protein extracts. Jurkat E6.1 cells (2 Â 10 6 per ml RPMI 1640 medium) were stimulated with gal-1 (20 mg/ml) at 371C and washed once with ice-cold phosphate-buffered saline (PBS). The cells were pelleted and solubilized with 0.1 ml 20 mM HEPES (pH 7.9; 10 mM KCl, 1 mM EDTA, 1 mM pefabloc, 0.1 mM Na 3 VO 4 , 0.2% Triton X-100, 10% glycerol, and 1 mg/ml each of aprotinin, pepstatin, and leupeptin) for 15 min on ice. 44 After centrifugation at 16 000 Â g for 2 min, the pellets were extracted for 20 min on ice with 50 ml 10 mM HEPES (pH 7.9; 350 mM NaCl, 10 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mM pefabloc, 0.1 mM Na 3 VO 4 , 20% glycerol, and 1 mg/ml each of aprotinin, pepstatin, and leupeptin). The extracts were centrifuged at 16 000 Â g for 5 min and stored at À801C.
Electrophoretic mobility shift assay. The double-stranded AP-1 consensus oligonucleotide (sc-2501) was 32 P-labelled with [g-32 P]ATP using T4 polynucleotide kinase. Nuclear extract (4 ml) was mixed with 20 ml of binding buffer (10 mM Tris-HCL (pH 7.5), 50 mM NaCl, 1 mM EDTA, 1 mM DDT, 0.1%Triton X-100, 5% glycerol, 1 mg/ml bovine serum albumin (BSA), and 2 mg/ml poly[dI-dC] containing 65 000 c.p.m. of end-labeled probe. For competition studies, the binding reactions were performed in the presence of 100-fold excess of unlabeled AP-1 consensus or mutant oligonucleotides. After 30 min on ice, the complexes were separated on a native 6% polyacrylamide gel. Dried gels were exposed to X-ray films (HT1.000G Plus; Agfa-Gevaert, Mortsel, Belgium) at À701C with intensifying screens.
ELISA-based detection and quantification of AP-1 transcription factor activation. The DNA-binding activity of AP-1 was quantified by ELISA using the Trans-AM AP-1 transcription factor assay. Nuclear extracts (5 mg per well) were incubated in 96-well plates coated with an immobilized oligonucleotide containing a TRE with the 5 0 -TGA(C/G)TCA-3 0 sequence that primarily binds AP-1 dimers. For assay specificity, binding reactions were performed in the presence of consensus and mutated oligonucleotides at 20 pM per well. AP-1 binding to the immobilized probe was detected by incubation with primary antibodies specific for c-Fos, c-Jun, Fos B, and Jun B. The c-Jun antibody detects phosphorylated c-Jun (Ser73) and JunD (Ser100). The addition of a secondary horseradish peroxidase (HRP)-conjugated antibody and developing solution provided a colorimetric readout that was spectrophotometrically quantified at 450 nm. Background binding was subtracted from the value obtained for binding to the consensus DNA sequence.
DNA extraction and analysis by agarose gel electrophoresis. Degraded low-molecular-weight DNA from apoptotic cells was selectively extracted with phosphatecitrate (PC) buffer. 45 The cells were collected by centrifugation, fixed in 70% ethanol, and were stored at À251C for 16 h. Then the cells were pelleted at 800 Â g for 5 min. Cell pellets (2 Â 10 6 cells) were suspended in 40 ml of PC buffer (0.2 M Na 2 HPO 4 adjusted with 0.1 M citric acid to pH 7.8) at room temperature for 30 min. After centrifugation at 1000 Â g for 5 min, supernatants were evaporated in a vacuum concentrator 5301 (Eppendorf, Hamburg, Germany) for 15 min. Then 3 ml 0.25% NP-40 was added to the cell extract followed by 3 ml of a solution of RNase A (1 mg/ml). After 30 min incubation at 371C, 3 ml of a solution of proteinase K (1 mg/ml) was added and the extract was incubated for additional 30 min at 371C. Then the extracts were mixed with 12 ml loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol) and subjected to 1.5% agarose gel electrophoresis. DNA ladders were visualized by ethidium bromide staining under UV light.
JNK immune complex kinase assay. Jurkat E6.1 cells (2 Â 10 6 per ml RPMI 1640 medium) were incubated for 30 min at 371C with 10 mM of the JNK inhibitor SP600125. Then the cells were stimulated with 30 mg/ml gal-1. Cell pellets Figure 8 Effects of galectin-1 (gal-1) on initiator procaspase-9 and effector procaspase-3 processing and inhibition by the ATP-competitive inhibitor of c-Jun Nterminal kinase (JNK) SP600125. Jurkat E6.1 cells (2 Â 10 6 per ml RPMI 1640 medium) were incubated with SP600125 for 30 min at 371C. Non-and inhibitortreated cells were stimulated with gal-1 as indicated. Control cells were incubated in medium alone. Cell extract proteins were analyzed on the blots with a cleaved caspase-9 (Asp315) polyclonal antibody (pAb) and with a cleaved caspase-3 (Asp175) rabbit monoclonal antibody (mAb). The bands were luminographically visualized on X-ray films by enhanced chemiluminescence (ECL). Equal loading of gel lanes was verified by reprobing the blots for expression of b-actin. Shown are representative blots from three independent experiments
Galectin-1 induced cell death via JNK/c-Jun/AP-1 B Brandt et al
